As of October 22, 2026, 5-MAPB is in a legal gray area (sold in practice, exposed to an interpretive ban theory) in District of Columbia. Analog-exposed - auto-Schedule I via D.C. Code 48-902.14 (5-APB twin named). Controlling source: D.C. Code Sec. 48-902.14 - Treatment of controlled substance analogues (auto-Schedule I).
Verified October 22, 2026 (hash check) · confidence: confirmedMechanism: 5-MAPB is NOT named. DC names the desmethyl/lower benzofuran homologs 5-APB, 5-APDB, 6-APB, 6-APDB at 48-902.04(3)(G-iv..vii) and MDA at (3)(F), but not the N-methyl 5-MAPB. Reached only by the operative controlled-substances-analogue statute 48-902.14(a), which auto-treats an analogue (substantially similar chemical structure to a Schedule I/II substance, and/or substantially similar/greater CNS effect) as a controlled substance in Schedule I to the extent intended for human consumption. Basis INTERPRETIVE (structurally strong: 5-MAPB is the N-methyl homolog of the named 5-APB and the benzofuran bioisostere of the named MDA). Loose zone: turns on the 'substantially similar chemical structure' finding under 48-902.14(b)(1) plus the human-consumption limiter. Correction vs seed: none; re-verified 48-902.14 and the named APB/APDB list verbatim against official DC Council code. Note the statutory definition term is 'controlled analogue' at (b), with the treatment clause at (a).
A controlled substances analogue shall, to the extent intended for human consumption, be treated for the purposes of any District of Columbia law as a controlled substance in Schedule I ... a substance with a chemical structure that is substantially similar to the chemical structure of a controlled substance in Schedule I or II (D.C. Code 48-902.14(a),(b)(1)); named parents 5-APB/5-APDB/6-APB/6-APDB at 48-902.04(3)(G-iv..vii), MDA at (3)(F)
Among District of Columbia's 2 neighbors, Virginia is illegal; Maryland is gray area.
Open the interactive map · Every compound in District of Columbia
Federal gray area. Unscheduled by name; Schedule I by Federal Analogue Act when intended for human consumption Federal detail
2 instruments on file for this compound's framework in District of Columbia; 3 of 3 citations above are official sources. Each text carries its source and a fingerprint that changes when the law does.
2a848ce471c86d2c**§ 48-902.04(3) (hallucinogen chapeau)** — "(3) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, its salts, isomers and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:" — D.C. Code § 48-902.04(3), https://code.dccouncil.gov/us/dc/council/code/sections/48-902.04 (OFFICIAL — DC Council). Psilocyn (3)(S) and even 4-AcO-DMT are listed; 4-HO-MET is not. **§ 48-902.14 (controlled substances analogue)** — "(a) A controlled substances analogue shall, to the extent intended for human consumption, be treated for the purposes of any District of Columbia law as a controlled substance in Schedule I. (b) … the term 'controlled analogue' means: (1) a substance with a chemical structure that is substantially similar to the chemical structure of a controlled substance in Schedule I or II; (2) A substance that has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than [that] of a controlled substance in Schedule I or II; or (3) A substance that … is represented to have or is intended to have [such effect] …" — D.C. Code § 48-902.14, https://code.dccouncil.gov/us/dc/council/code/sections/48-902.14 (OFFICIAL — DC Council).
8b8d79b80f81cf85(a) A controlled substances analogue shall, to the extent intended for human consumption, be treated for the purposes of any District of Columbia law as a controlled substance in Schedule I. (b) Except as provided in subsection (c) of this section, the term controlled analogue means: (1) a substance with a chemical structure that is substantially similar to the chemical structure of a controlled substance in Schedule I or II; (2) A substance that has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central system of a controlled substance in Schedule I or II; or (3) A substance that, with respect to a particular person, is represented to have or is intended to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to, or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or II. (c) Such term does not include: (1) A controlled substance; (2) Any substance for which there is an approved new drug application; (3) With respect to a particular person any substance, if an exemption is in effect for investigational use, for that person, under Section 505 of the Federal Food, Drug, and Cosmetic Act, approved June 25, 1938 (52 Stat. 1052, 21 U.S.C. Section 355) to the extent conduct with respect to such substance is pursuant to such exemption; or (4) Any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance.
Compound Laws, published by Compound Analytics, reports the record: statutes verbatim, official citations, enforcement facts and verification dates. Nothing here is legal advice and nothing here describes how to get around a law. A jurisdiction with no verified row is reported as not yet verified, never as legal. Found an error? Corrections policy.
About · Methodology · Glossary · Changes · Data & API · llms.txt · Sitemap